Overview

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)

Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the effect of mitapivat versus placebo on transfusion burden in participants with transfusion-dependent alpha- or beta-thalassemia (TDT).
Phase:
Phase 3
Details
Lead Sponsor:
Agios Pharmaceuticals, Inc.